Skip to main content

Mounjaro, Is it a game changer for weight loss and diabetes?

 MOUNJARO™ (Tirzepatide) was approved for medical use in the United States in May 2022


WEIGHT LOSS: (Not approved by FDA for weight loss)

Eli Lilly and Company is finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management.





MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management.

CONTRAINDICATIONS

  • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 
  • Known serious all to tirzepatide or any of the excipients in MOUNJARO
                                                          ADVERSE REACTIONS
Risk of Thyroid C-cell Tumors, hypoglycemia, pancreatitis, and GI problems

                                                           

PRECAUTIONS and DOSAGE

1. Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected
2. Severe Gastrointestinal Disease: Use may be associated with gastrointestinal adverse reactions, sometimes severe, resulting in dehydration leading to acute kidney disease   
3. Acute Gallbladder Disease: Has occurred in clinical trials.

  • The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. 
  • After 4 weeks, a dosage to 5 mg injected subcutaneously once weekly is prescribed.
                                                            DRUG INTERACTIONS

Insulin secretagogues (e.g., sulfonylureas) or insulin may interact causing hypoglycemia

                                                            Renal/Hepatic Impairment


No dosage adjustment required

Comments

Post a Comment

Popular posts from this blog

Thyroid health- Quality of Life

  Let's get a TSH blood test for our family and friends Normal serum TSH ranges are higher in the  people age 70 to 80 years ; based on this, higher serum TSH goals may be needed as a patient ages.  The American Thyroid Association (ATA) suggests raising the target serum TSH to 4-6 m IU/L for 70 years-old and up The thyroid is a small, butterfly-shaped hormone-producing gland located at the front of the neck. The thyroid gland secretes two main hormones:  thyroxine (T-4) and triiodothyronine (T-3).   These hormones regulate energy levels, metabolism of fats, proteins and carbohydrates, body temperature, heart rate.  Hypothyroidism happens when the underactive thyroid gland doesn't make enough hormones. Hypothyroidism affects up to 10% of the general population (5% undiagnosed) . A n autoimmune disease called Hashimoto's diseas e where our body  makes antibodies that attack healthy thyroid tissues  is the most common cause of hypothyroidism in soc...
Post a Comment
Read more

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk.   In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk (  Andrus & Lacaille, 2014  )  The guideline classifies statin therapy as  high-intensity (lowers LD...
7 comments
Read more